PharmiWeb Recruiter Blog

New Boston office strengthens position in US market, providing local support and greater responsiveness for clinical trials

Company plans to meet US and international customers during DIA (Drug Information Association) International Congress in Chicago, June 19 to 23

Nancy, France,June 15, 2022 – The Banook Group, specialized in cardiac safety, clinical imaging and endpoint adjudication, today announces the opening of its first US office in Boston, Massachusetts. This is the third international office for Banook since its inception in 1999, adding to its headquarters in Nancy (France), and locations in Munich (Germany) and Montreal (Canada).

About 40% of Banook’s customers are based in the US. The opening of the Boston office aims to reduce the constraints of time zones and to provide enhanced technical and logistics support. It will allow the company to offer local support to its 70 current US customers and to grow in the North American market. This follows the opening of a Canadian office in 2017, increasing availability across the North American continent to meet clients’ needs.

“Our team is very excited about this next logical step,” said Alexandre Durand-Salmon, CEO of the Banook Group. “Our high-quality core lab services are designed to fit the rapidly evolving needs of our clients today. A local presence gives us the right edge to establish ourselves as industry experts in the US. We have received terrific support and expressions of interest from prospects and customers who have been trying to source these types of turnkey services.”

These clients and prospects are laboratories and CROs wishing to measure the cardiac safety of their molecules; also to centralize their medical imaging and endpoint adjudication, and to conduct virtual clinical trial projects, which have been increasing in number since COVID-19. The Banook Group has developed a complete clinical study support process, including project setup and management; offering logistics, devices, support and analysis by experts up to and including conclusion with data management.

This new point of contact confirms Banook’s objective to be close to its clients, both geographically and in terms of clinical project management. With 32% of global clinical trials located in the United States, this will allow the Group to be even more reactive in the follow-up of clinical studies in this dynamic market. The North American clinical trials market forecasts a CAGR of 7.4% during the period of 2022-2027, with 11,865 active clinical trials in 2020, across various phases for cancer indications.

The Boston team has already attended various conferences and joined business associations for clinical studies, including the upcoming Drug and Information Association (DIA) International Congress in Chicago from June 19 to 23, 2022; where the Banook Group will be present at booth 2223.

About Banook Group

Ingelheim, Germany and San Diego, CA, June 14, 2022 – Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech company.  

• STRATEGIC PARTNERSHIP LEVERAGES EVOTEC’S PROPRIETARY PLATFORM CAPABILITIES IN THE FIELD OF PROTEIN HOMEOSTASIS

Hamburg, Germany, 14 June 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Evotec’s innovative TargetAlloMod platforms will be evaluated to discover first-in-class novel mode of action therapeutic candidates. The agreement was facilitated by Johnson & Johnson Innovation.

Under the agreement, Evotec and Janssen will jointly conduct screens on the identified targets and collaborate with hit identification and lead optimisation of the most promising chemical assets, leveraging Evotec’s end-to-end integrated drug discovery and development platform.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are very proud to enter into this collaboration to explore unique approaches to high potential cell surface drug targets with novel therapeutic modalities and to deliver and make innovative therapeutic options available to patients.”

Besides research funding, Evotec is entitled to success-based research and commercial milestones up to approximately € 210 m per project as well as tiered royalties on products resulting from this collaboration.

About TargetAlloMod
Scientists at Evotec have discovered that for certain extracellular receptors, small molecules can bind allosterically and induce a natural proteolytic cleavage process to shed the ectodomain. This results in the disruption of cell signalling and the shed ectodomain can, in many cases, further act as a sink for the native ligand of the targeted receptor. The TargetAlloMod platform comprises a suite of proprietary assay principles and computational tools to assess and screen extracellular receptor targets for shedding and the induction of shedding by small molecule allosteric modulators. This platform has broad applicability across many therapeutic areas.

ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,200 highly qualified people. The Company’s 15 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

A 2021 Mercer survey reported that 87% of life science companies were planning to offer part-time remote working models in the future. In 2022, remote working opportunities across the industry are continuously rising, with companies such as IQVIA, Worldwide Clinical Trials and Syneos Health advertising homeworking roles across the globe.  

WILMINGTON, N.C., June 08, 2022 - The PPD clinical research business of Thermo Fisher Scientific has been named Clinical Research Company of the Year at the 2022 PharmaTimes Clinical Researcher of the Year International competition held recently in London.

Paris, June 8, 2022. Sanofi announces the launch of its first Digital Accelerator to foster its ambition to become a leading digital healthcare company. The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI). Based in Paris, it already brings together a team of over 75 experts from around the world and will continue to recruit top talent in digital product management, full stack development, and data science.

It’s been a busy few years at PharmiWeb as we continue our growth on a global scale. After establishing ourselves as a leading Life Science job board, we have been focused on developing our entire range of Talent Acquisition solutions, introducing new features and resources to help our clients continue to locate and engage the best talent in the industry.

Coriolis Pharma is substantially expanding its current headquarters with additional facilities to form a new Campus.

Cambridge, UK, June 6, 2022 – SMC Ltd., a leading solutions provider in the manufacturing of pharmaceutical and medical devices, announces the opening of Cambridge Pharma, a new business offering pharmaceutical development services, including sterile fill-finish. The new 20,000 sq ft facility, located at the Cambridge Research Park, UK, includes a purpose-built sterile fill-finish facility, a process development laboratory and an analytical laboratory. Services include process development and scale up, sterile fill finish for clinical trials, QC and stability testing and QP release of clinical trials supplies.

On 23 June 2021 at its Investor Update, GSK plc (“GSK” or the “Company”) confirmed its intention to separate its Consumer Healthcare business from the GSK Group to form Haleon plc (“Haleon”), an independent listed company. It is proposed that the separation will be effected by way of a demerger (the “Demerger”) of at least 80 per cent. of GSK’s 68 per cent. holding in the Consumer Healthcare business to GSK shareholders. The Consumer Healthcare business is currently a joint venture between GSK and Pfizer Inc (“Pfizer”), with GSK holding a majority controlling interest of 68 per cent. and Pfizer holding 32 per cent.